{"id":7665,"date":"2020-02-06T08:00:04","date_gmt":"2020-02-06T08:00:04","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum\/"},"modified":"2020-02-06T08:00:04","modified_gmt":"2020-02-06T08:00:04","slug":"nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum\/","title":{"rendered":"Nicox : Pr\u00e9sentation des r\u00e9sultats de l\u2019\u00e9tude clinique de phase 2 du NCX 470 au Glaucoma 360 New Horizons Forum"},"content":{"rendered":"<p>Sophia Antipolis, France<\/p>\n<p><strong>Nicox SA<\/strong> (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, a annonc\u00e9 aujourd\u2019hui que le Dr. Tomas Navratil, PhD., <em>Executive Vice President, Head of R&amp;D <\/em>du groupe Nicox et <em>General Manager<\/em> de Nicox Ophthalmics, Inc., pr\u00e9sentera les r\u00e9sultats de l\u2019\u00e9tude clinique Dolomites de phase 2 du NCX 470 dans le cadre de la session \u201c<em>New Horizons in Pharmaceuticals<\/em>\u201d de la r\u00e9union annuelle du <em>Glaucoma 360 New Horizons Forum <\/em>qui se tiendra le 7 f\u00e9vrier 2020 \u00e0 San Francisco, Etats-Unis.<\/p>\n<p>NCX 470, un nouvel analogue de bimatoprost donneur d\u2019oxyde nitrique (NO) de seconde g\u00e9n\u00e9ration, pour la r\u00e9duction de la pression intraoculaire (PIO) chez les patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire est le principal programme en d\u00e9veloppement clinique de Nicox. La solution ophtalmique de NCX 470 \u00e0 0,065% a d\u00e9montr\u00e9 une non-inf\u00e9riorit\u00e9 et une sup\u00e9riorit\u00e9 statistique sur la solution ophtalmique de latanoprost \u00e0 0,005%, le leader du march\u00e9 am\u00e9ricain en termes de prescriptions d\u2019analogues de prostaglandine, dans l\u2019\u00e9tude clinique Dolomites, une \u00e9tude clinique de phase 2, de s\u00e9curit\u00e9 et d\u2019efficacit\u00e9, multicentrique, men\u00e9e aux Etats-Unis.<\/p>\n<p>Une r\u00e9union de fin de phase 2 avec la <em>Food and Drug Administration <\/em>(FDA) am\u00e9ricaine est pr\u00e9vue au premier trimestre 2020. L\u2019initiation de la premi\u00e8re des deux \u00e9tudes cliniques de phase 3 (l\u2019\u00e9tude \u00ab\u00a0Mont Blanc\u00a0\u00bb) est attendue d\u2019ici la fin du deuxi\u00e8me trimestre 2020.<\/p>\n<p>La pr\u00e9sentation sera disponible sur le site internet de Nicox dans la section \u201c<a href=\"\/?page_id=310077\">Pr\u00e9sentations et Ev\u00e8nements<\/a>\u201d.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, a annonc\u00e9 aujourd\u2019hui que le Dr. Tomas Navratil, PhD., Executive Vice President, Head of R&amp;D du groupe Nicox et General Manager de Nicox Ophthalmics, Inc., pr\u00e9sentera les r\u00e9sultats de l\u2019\u00e9tude clinique Dolomites de phase 2 du NCX 470 dans [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-7665","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox : Pr\u00e9sentation des r\u00e9sultats de l\u2019\u00e9tude clinique de phase 2 du NCX 470 au Glaucoma 360 New Horizons Forum - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox : Pr\u00e9sentation des r\u00e9sultats de l\u2019\u00e9tude clinique de phase 2 du NCX 470 au Glaucoma 360 New Horizons Forum - Nicox\" \/>\n<meta property=\"og:description\" content=\"Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, a annonc\u00e9 aujourd\u2019hui que le Dr. Tomas Navratil, PhD., Executive Vice President, Head of R&amp;D du groupe Nicox et General Manager de Nicox Ophthalmics, Inc., pr\u00e9sentera les r\u00e9sultats de l\u2019\u00e9tude clinique Dolomites de phase 2 du NCX 470 dans [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2020-02-06T08:00:04+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox : Pr\u00e9sentation des r\u00e9sultats de l\u2019\u00e9tude clinique de phase 2 du NCX 470 au Glaucoma 360 New Horizons Forum\",\"datePublished\":\"2020-02-06T08:00:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum\\\/\"},\"wordCount\":280,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum\\\/\",\"name\":\"Nicox : Pr\u00e9sentation des r\u00e9sultats de l\u2019\u00e9tude clinique de phase 2 du NCX 470 au Glaucoma 360 New Horizons Forum - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-02-06T08:00:04+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox : Pr\u00e9sentation des r\u00e9sultats de l\u2019\u00e9tude clinique de phase 2 du NCX 470 au Glaucoma 360 New Horizons Forum - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox : Pr\u00e9sentation des r\u00e9sultats de l\u2019\u00e9tude clinique de phase 2 du NCX 470 au Glaucoma 360 New Horizons Forum - Nicox","og_description":"Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, a annonc\u00e9 aujourd\u2019hui que le Dr. Tomas Navratil, PhD., Executive Vice President, Head of R&amp;D du groupe Nicox et General Manager de Nicox Ophthalmics, Inc., pr\u00e9sentera les r\u00e9sultats de l\u2019\u00e9tude clinique Dolomites de phase 2 du NCX 470 dans [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum\/","og_site_name":"Nicox","article_published_time":"2020-02-06T08:00:04+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum\/"},"author":{"name":"","@id":""},"headline":"Nicox : Pr\u00e9sentation des r\u00e9sultats de l\u2019\u00e9tude clinique de phase 2 du NCX 470 au Glaucoma 360 New Horizons Forum","datePublished":"2020-02-06T08:00:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum\/"},"wordCount":280,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum\/","url":"https:\/\/www.nicox.com\/fr\/nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum\/","name":"Nicox : Pr\u00e9sentation des r\u00e9sultats de l\u2019\u00e9tude clinique de phase 2 du NCX 470 au Glaucoma 360 New Horizons Forum - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2020-02-06T08:00:04+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-presentation-des-resultats-de-letude-clinique-de-phase-2-du-ncx-470-au-glaucoma-360-new-horizons-forum\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7665"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7665\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7665"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7665"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}